BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27431203)

  • 21. E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness.
    Rosso M; Majem B; Devis L; Lapyckyj L; Besso MJ; Llauradó M; Abascal MF; Matos ML; Lanau L; Castellví J; Sánchez JL; Pérez Benavente A; Gil-Moreno A; Reventós J; Santamaria Margalef A; Rigau M; Vazquez-Levin MH
    PLoS One; 2017; 12(9):e0184439. PubMed ID: 28934230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions.
    Stadlmann S; Amberger A; Pollheimer J; Gastl G; Offner FA; Margreiter R; Zeimet AG
    Gynecol Oncol; 2005 Jun; 97(3):784-9. PubMed ID: 15943987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Malignant ascites in ovarian cancer and the role of targeted therapeutics.
    Smolle E; Taucher V; Haybaeck J
    Anticancer Res; 2014 Apr; 34(4):1553-61. PubMed ID: 24692682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
    Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
    Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
    Artini PG; Ruggiero M; Monteleone P; Carpi A; Cristello F; Cela V; Genazzani AR
    Biomed Pharmacother; 2008; 62(6):373-7. PubMed ID: 18037256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.
    Pourgholami MH; Yan Cai Z; Lu Y; Wang L; Morris DL
    Clin Cancer Res; 2006 Mar; 12(6):1928-35. PubMed ID: 16551879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
    Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
    Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitochondria-related oxidative stress contributes to ovarian cancer-promoting activity of mesothelial cells subjected to malignant ascites.
    Pakuła M; Mikuła-Pietrasik J; Stryczyński Ł; Uruski P; Szubert S; Moszyński R; Szpurek D; Sajdak S; Tykarski A; Książek K
    Int J Biochem Cell Biol; 2018 May; 98():82-88. PubMed ID: 29550585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stem-like tumor cells and proinflammatory cytokines in the ascitic fluid of ovarian cancer patients.
    Gening SO; Abakumova TV; Antoneeva II; Rizvanov AA; Gening TP; Gafurbaeva DU
    Klin Lab Diagn; 2021 May; 66(5):297-303. PubMed ID: 34047516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation.
    Ricciardelli C; Lokman NA; Cheruvu S; Tan IA; Ween MP; Pyragius CE; Ruszkiewicz A; Hoffmann P; Oehler MK
    Clin Exp Metastasis; 2015 Jun; 32(5):441-55. PubMed ID: 25895698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation.
    Nagy JA; Herzberg KT; Dvorak JM; Dvorak HF
    Cancer Res; 1993 Jun; 53(11):2631-43. PubMed ID: 8495427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study.
    Topalak O; Saygili U; Soyturk M; Karaca N; Batur Y; Uslu T; Erten O
    Gynecol Oncol; 2002 Apr; 85(1):108-13. PubMed ID: 11925128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Ascites May Provide Useful Information for Diagnosis of Ovarian Cancer].
    Stuchlíková E; Zahradníková M; Nenutil R; Valík D; Vojtěšek B; Novotný M; Hernychova L
    Klin Onkol; 2017; 30(Supplementum1):187-190. PubMed ID: 28471203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks.
    Naldini A; Morena E; Belotti D; Carraro F; Allavena P; Giavazzi R
    Thromb Haemost; 2011 Oct; 106(4):705-11. PubMed ID: 21833453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
    Giuntoli RL; Webb TJ; Zoso A; Rogers O; Diaz-Montes TP; Bristow RE; Oelke M
    Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acidic ascites inhibits ovarian cancer cell proliferation and correlates with the metabolomic, lipidomic and inflammatory phenotype of human patients.
    Yang Q; Bae G; Nadiradze G; Castagna A; Berezhnoy G; Zizmare L; Kulkarni A; Singh Y; Weinreich FJ; Kommoss S; Reymond MA; Trautwein C
    J Transl Med; 2022 Dec; 20(1):581. PubMed ID: 36503580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytological Findings of Ascitic Fluid with a Malignant Ovarian Steroid Cell Tumor: A Case Report and Literature Review.
    Kosaka N; Hasegawa K; Kiuchi K; Ochiai S; Nagai T; Machida H; Imai Y; Fukasawa I
    Acta Cytol; 2017; 61(2):165-171. PubMed ID: 28343229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles.
    Graves LE; Ariztia EV; Navari JR; Matzel HJ; Stack MS; Fishman DA
    Cancer Res; 2004 Oct; 64(19):7045-9. PubMed ID: 15466198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
    Boss EA; Massuger LF; Thomas CM; Geurts-Moespot A; van Schaik JH; Boonstra H; Sweep CG
    Anticancer Res; 2002; 22(1A):275-82. PubMed ID: 12017303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [-Cytokine level in malignant ascites and peripheral blood of patients with advanced ovarian carcinoma-].
    Radke J; Schmidt D; Böhme M; Schmidt U; Weise W; Morenz J
    Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):83-7. PubMed ID: 8647364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.